Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EH04
|
| gptkbp:brand |
Nerlynx
|
| gptkbp:CASNumber |
698387-09-6
|
| gptkbp:chemicalFormula |
C30H29ClN6O3
|
| gptkbp:contraindication |
hypersensitivity to neratinib
|
| gptkbp:developer |
Puma Biotechnology
|
| gptkbp:drugInteraction |
CYP3A4 inhibitors
CYP3A4 inducers |
| gptkbp:eliminationHalfLife |
7-17 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
neratinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
irreversible inhibitor of HER2 and EGFR
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:molecularWeight |
557.04 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain fatigue |
| gptkbp:synonym |
HKI-272
|
| gptkbp:usedFor |
gptkb:cancer
gptkb:HER2-positive_breast_cancer |
| gptkbp:bfsParent |
gptkb:P42338
|
| gptkbp:bfsLayer |
6
|